Blair William & Co. IL Sells 106,111 Shares of Hologic, Inc. (NASDAQ:HOLX)

Blair William & Co. IL lessened its holdings in Hologic, Inc. (NASDAQ:HOLX) by 42.9% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 141,287 shares of the medical equipment provider’s stock after selling 106,111 shares during the period. Blair William & Co. IL’s holdings in Hologic were worth $10,185,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. General Partner Inc. bought a new position in Hologic in the fourth quarter worth approximately $26,000. Venturi Wealth Management LLC increased its stake in shares of Hologic by 156.3% in the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock worth $31,000 after purchasing an additional 261 shares in the last quarter. EverSource Wealth Advisors LLC raised its holdings in Hologic by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock worth $42,000 after purchasing an additional 260 shares during the period. Smartleaf Asset Management LLC lifted its position in Hologic by 36.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock valued at $43,000 after purchasing an additional 159 shares in the last quarter. Finally, Smithfield Trust Co grew its holdings in Hologic by 160.0% during the fourth quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider’s stock valued at $45,000 after purchasing an additional 400 shares during the period. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Stock Performance

NASDAQ HOLX opened at $61.32 on Friday. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. Hologic, Inc. has a 1-year low of $60.34 and a 1-year high of $84.67. The business has a 50 day simple moving average of $65.24 and a two-hundred day simple moving average of $73.29. The stock has a market capitalization of $13.76 billion, a PE ratio of 19.34, a P/E/G ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, research analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently commented on HOLX. Leerink Partners downgraded Hologic from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $80.00 to $75.00 in a research note on Thursday, February 6th. William Blair restated an “outperform” rating on shares of Hologic in a research note on Thursday, February 6th. Evercore ISI dropped their price target on shares of Hologic from $76.00 to $73.00 and set an “in-line” rating for the company in a research report on Thursday, February 6th. Stephens restated an “overweight” rating and set a $84.00 price objective on shares of Hologic in a research report on Thursday, February 6th. Finally, Raymond James restated an “outperform” rating and set a $90.00 target price (down previously from $95.00) on shares of Hologic in a research note on Thursday, February 6th. Eleven analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $84.62.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.